PinkDx is an early-stage company based in Daly City, California that applies advanced science and technology to address medical problems unique to women. Its lead program is a diagnostic test intended to clarify diagnoses for women who present with general symptoms that may signal a gynecologic cancer. The company aims to replace invasive diagnostic procedures, reduce delays in obtaining answers, and enable faster, more appropriate care for patients and physicians. PinkDx reports progress in discovery and development and is advancing the test toward clinical validation. The company completed an upsized Series A round totaling $45 million to support development and clinical validation toward commercialization. As part of BEVC's investment, PinkDx joined Bakar Labs, linking the company to UC Berkeley's life-science incubator and strategic resources. PinkDx is an early-stage, Daly City, CA–based company focused on positively impacting the health of women across their life journey. Led by cofounder, chairwoman and CEO Bonnie Anderson, with CSO Giulia C. Kennedy, Ph.D., and CFO/Chief Business Officer Tim McMeekan, the company applies scientific approaches to address medical problems affecting women. Its first indication targets overcoming diagnostic challenges for women who present with general symptoms that could signal a gynecological cancer. PinkDx will use the Series A proceeds to advance test development, initially focusing on gynecological cancers. The company also appointed Alison Cowan, M.D., M.S.C.R., as chief medical officer to guide clinical development; she previously led Medical Affairs at Mirvie and served as medical director for Hologic’s Diagnostics division.

Total raised

$45M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2025